Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Gastrointestinal varices causes

Introduction

Overview

Overview

Causes of gastointestinal varices include all the causes of increased portal venous pressure, which may be divided into cirrhotic and non-cirrhotic causes.

Causes

Causes

Cirrhotic causes

Non-cirrhotic causes

Pre-hepatic causes

Intrahepatic causes[1][5][6][7][8][9][10][11][12][13][14][17][18][19][20]

Post-hepatic:[3][4]

References

References

  1. ↑ 1.0 1.1 Li X, Gao W, Chen J, Tang W (2000). “[Non-cirrhotic portal hypertension associated with autoimmune disease]”. Zhonghua Wai Ke Za Zhi (in Chinese). 38 (2): 101–3. PMIDΒ 11831999.
  2. ↑ Kono K, Ohnishi K, Omata M, Saito M, Nakayama T, Hatano H, Nakajima Y, Sugita S, Okuda K (1988). “Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits”. Gastroenterology. 94 (3): 787–96. PMIDΒ 3276575.
  3. ↑ 3.0 3.1 Kumar S, Joshi R, Jain AP (2007). “Portal hypertension associated with sickle cell disease”. Indian J Gastroenterol. 26 (2): 94. PMIDΒ 17558079.
  4. ↑ 4.0 4.1 Bayan K, TΓΌzΓΌn Y, Yilmaz S, Canoruc N, Dursun M (2009). “Analysis of inherited thrombophilic mutations and natural anticoagulant deficiency in patients with idiopathic portal hypertension”. J. Thromb. Thrombolysis. 28 (1): 57–62. doi:10.1007/s11239-008-0244-8. PMIDΒ 18685811.
  5. ↑ 5.0 5.1 Girard M, Amiel J, Fabre M, Pariente D, Lyonnet S, Jacquemin E (2005). “Adams-Oliver syndrome and hepatoportal sclerosis: occasional association or common mechanism?”. Am. J. Med. Genet. A. 135 (2): 186–9. doi:10.1002/ajmg.a.30724. PMIDΒ 15832360.
  6. ↑ 6.0 6.1 Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbonero L, Barreiro P, Mura MS, Babudieri S, Albertos S, Garcia-Samaniego J, Soriano V (2008). “Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome”. Antivir. Ther. (Lond.). 13 (1): 103–7. PMIDΒ 18389904.
  7. ↑ 7.0 7.1 Nevens F, Fevery J, Van Steenbergen W, Sciot R, Desmet V, De Groote J (1990). “Arsenic and non-cirrhotic portal hypertension. A report of eight cases”. J. Hepatol. 11 (1): 80–5. PMIDΒ 2398270.
  8. ↑ 8.0 8.1 Fuss IJ, Friend J, Yang Z, He JP, Hooda L, Boyer J, Xi L, Raffeld M, Kleiner DE, Heller T, Strober W (2013). “Nodular regenerative hyperplasia in common variable immunodeficiency”. J. Clin. Immunol. 33 (4): 748–58. doi:10.1007/s10875-013-9873-6. PMCΒ 3731765. PMIDΒ 23420139.
  9. ↑ 9.0 9.1 Vaiphei K, Bhatia A, Sinha SK (2011). “Liver pathology in collagen vascular disorders highlighting the vascular changes within portal tracts”. Indian J Pathol Microbiol. 54 (1): 25–31. doi:10.4103/0377-4929.77319. PMIDΒ 21393872.
  10. ↑ 10.0 10.1 De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA (2008). “Histopathology of liver biopsies from a thiopurine-naΓ―ve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia”. Scand. J. Gastroenterol. 43 (5): 604–8. doi:10.1080/00365520701800266. PMIDΒ 18415755.
  11. ↑ 11.0 11.1 Sarin SK, Mehra NK, Agarwal A, Malhotra V, Anand BS, Taneja V (1987). “Familial aggregation in noncirrhotic portal fibrosis: a report of four families”. Am. J. Gastroenterol. 82 (11): 1130–3. PMIDΒ 3499813.
  12. ↑ 12.0 12.1 Imai Y, Minami Y, Miyoshi S, Kawata S, Saito R, Noda S, Tamura S, Nishikawa M, Tajima K, Tarui S (1986). “Idiopathic portal hypertension associated with Hashimoto’s disease: report of three cases”. Am. J. Gastroenterol. 81 (9): 791–5. PMIDΒ 2944377.
  13. ↑ 13.0 13.1 Siramolpiwat S, Seijo S, Miquel R, Berzigotti A, Garcia-Criado A, Darnell A, Turon F, Hernandez-Gea V, Bosch J, Garcia-PagΓ‘n JC (2014). “Idiopathic portal hypertension: natural history and long-term outcome”. Hepatology. 59 (6): 2276–85. doi:10.1002/hep.26904. PMIDΒ 24155091.
  14. ↑ 14.0 14.1 de Lonlay P, Seta N (2009). “The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib”. Biochim. Biophys. Acta. 1792 (9): 841–3. doi:10.1016/j.bbadis.2008.11.012. PMIDΒ 19101627.
  15. ↑ Allison MC, Mowat A, McCruden EA, McGregor E, Burt AD, Briggs JD, Junor BJ, Follett EA, MacSween RN, Mills PR (1992). “The spectrum of chronic liver disease in renal transplant recipients”. Q. J. Med. 83 (301): 355–67. PMIDΒ 1438671.
  16. ↑ Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R (1994). “Nodular regenerative hyperplasia of the liver graft after liver transplantation”. Hepatology. 20 (1 Pt 1): 88–94. PMIDΒ 8020909.
  17. ↑ 17.0 17.1 Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF (2007). “Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine”. Gut. 56 (10): 1404–9. doi:10.1136/gut.2006.114363. PMCΒ 2000290. PMIDΒ 17504943.
  18. ↑ 18.0 18.1 Calabrese E, Hanauer SB (2011). “Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease”. J Crohns Colitis. 5 (1): 48–53. doi:10.1016/j.crohns.2010.08.007. PMIDΒ 21272804.
  19. ↑ 19.0 19.1 Roulot D (2013). “Liver involvement in Turner syndrome”. Liver Int. 33 (1): 24–30. doi:10.1111/liv.12007. PMIDΒ 23121401.
  20. ↑ 20.0 20.1 Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C (1991). “Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases”. Gastroenterology. 100 (6): 1701–9. PMIDΒ 2019375.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]